Structural myocardial alterations in diabetes and hypertension: the role of galectin-3
Само за регистроване кориснике
2014
Аутори
Seferović, JelenaLalić, Nebojša M.
Floridi, Federico
Tesić, Milorad
Seferović, Petar M.
Giga, Vojislav
Lalić, Katarina
Jotić, Aleksandra
Jovičić, Snežana
Colak, Emina
Salerno, Gerardo
Cardelli, Patrizia
Di Somma, Salvatore
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Background: Galectin-3 is a protein widely distributed in the heart, brain and blood vessels, and has a regulatory role in inflammation, immunology and cancer. Many studies demonstrated that the increased level of galectin-3 is associated with progressive fibrosis and stiffening of the myocardium. The aim of this study was to investigate the role of galectin-3 in patients with type 2 diabetes (T2D) and/or arterial hypertension (HT). Methods: Study population included 189 patients, with no coronary artery disease, divided into three groups: group 1 (T2D), group 2 (T2D+HT), and group 3 (HT). All subjects underwent routine laboratory tests, as well as specific biomarkers assessment [galectin-3, glycosylated hemoglobin (HbA(1c)), N- terminal fragment B-type natriuretic peptide (NT-proBNP)]. Cardiological evaluation included physical examination, transthoracic tissue Doppler echocardiography and stress echocardiography. Results: The results of this study demonstrated significantly increased... levels of galectin-3, blood glucose, and HbA(1c) in group 2. Also, echocardiographicaly, left ventricular (LV) diameters and IVS thickness were increased in this group of patients. Furthermore, in the same cohort a positive correlation between galectin-3 and NT-pro BNP, and galectin-3 and LV mass were demonstrated. In addition, a negative correlation between galectin-3 and LV end-diastolic diameter was revealed. Conclusions: This study revealed that levels of galectin-3 were higher in patients with both T2D and HT, and correlated with LV mass, indicating the potential role of this biomarker for early detection of myocardial structural and functional alterations.
Кључне речи:
galectin-3 / hypertension / myocardial fibrosis / type 2 diabetesИзвор:
Clinical Chemistry and Laboratory Medicine, 2014, 52, 10, 1499-1505Издавач:
- Walter de Gruyter Gmbh, Berlin
DOI: 10.1515/cclm-2014-0265
ISSN: 1434-6621
PubMed: 24887961
WoS: 000341683500017
Scopus: 2-s2.0-84921353607
Институција/група
PharmacyTY - JOUR AU - Seferović, Jelena AU - Lalić, Nebojša M. AU - Floridi, Federico AU - Tesić, Milorad AU - Seferović, Petar M. AU - Giga, Vojislav AU - Lalić, Katarina AU - Jotić, Aleksandra AU - Jovičić, Snežana AU - Colak, Emina AU - Salerno, Gerardo AU - Cardelli, Patrizia AU - Di Somma, Salvatore PY - 2014 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2074 AB - Background: Galectin-3 is a protein widely distributed in the heart, brain and blood vessels, and has a regulatory role in inflammation, immunology and cancer. Many studies demonstrated that the increased level of galectin-3 is associated with progressive fibrosis and stiffening of the myocardium. The aim of this study was to investigate the role of galectin-3 in patients with type 2 diabetes (T2D) and/or arterial hypertension (HT). Methods: Study population included 189 patients, with no coronary artery disease, divided into three groups: group 1 (T2D), group 2 (T2D+HT), and group 3 (HT). All subjects underwent routine laboratory tests, as well as specific biomarkers assessment [galectin-3, glycosylated hemoglobin (HbA(1c)), N- terminal fragment B-type natriuretic peptide (NT-proBNP)]. Cardiological evaluation included physical examination, transthoracic tissue Doppler echocardiography and stress echocardiography. Results: The results of this study demonstrated significantly increased levels of galectin-3, blood glucose, and HbA(1c) in group 2. Also, echocardiographicaly, left ventricular (LV) diameters and IVS thickness were increased in this group of patients. Furthermore, in the same cohort a positive correlation between galectin-3 and NT-pro BNP, and galectin-3 and LV mass were demonstrated. In addition, a negative correlation between galectin-3 and LV end-diastolic diameter was revealed. Conclusions: This study revealed that levels of galectin-3 were higher in patients with both T2D and HT, and correlated with LV mass, indicating the potential role of this biomarker for early detection of myocardial structural and functional alterations. PB - Walter de Gruyter Gmbh, Berlin T2 - Clinical Chemistry and Laboratory Medicine T1 - Structural myocardial alterations in diabetes and hypertension: the role of galectin-3 VL - 52 IS - 10 SP - 1499 EP - 1505 DO - 10.1515/cclm-2014-0265 ER -
@article{ author = "Seferović, Jelena and Lalić, Nebojša M. and Floridi, Federico and Tesić, Milorad and Seferović, Petar M. and Giga, Vojislav and Lalić, Katarina and Jotić, Aleksandra and Jovičić, Snežana and Colak, Emina and Salerno, Gerardo and Cardelli, Patrizia and Di Somma, Salvatore", year = "2014", abstract = "Background: Galectin-3 is a protein widely distributed in the heart, brain and blood vessels, and has a regulatory role in inflammation, immunology and cancer. Many studies demonstrated that the increased level of galectin-3 is associated with progressive fibrosis and stiffening of the myocardium. The aim of this study was to investigate the role of galectin-3 in patients with type 2 diabetes (T2D) and/or arterial hypertension (HT). Methods: Study population included 189 patients, with no coronary artery disease, divided into three groups: group 1 (T2D), group 2 (T2D+HT), and group 3 (HT). All subjects underwent routine laboratory tests, as well as specific biomarkers assessment [galectin-3, glycosylated hemoglobin (HbA(1c)), N- terminal fragment B-type natriuretic peptide (NT-proBNP)]. Cardiological evaluation included physical examination, transthoracic tissue Doppler echocardiography and stress echocardiography. Results: The results of this study demonstrated significantly increased levels of galectin-3, blood glucose, and HbA(1c) in group 2. Also, echocardiographicaly, left ventricular (LV) diameters and IVS thickness were increased in this group of patients. Furthermore, in the same cohort a positive correlation between galectin-3 and NT-pro BNP, and galectin-3 and LV mass were demonstrated. In addition, a negative correlation between galectin-3 and LV end-diastolic diameter was revealed. Conclusions: This study revealed that levels of galectin-3 were higher in patients with both T2D and HT, and correlated with LV mass, indicating the potential role of this biomarker for early detection of myocardial structural and functional alterations.", publisher = "Walter de Gruyter Gmbh, Berlin", journal = "Clinical Chemistry and Laboratory Medicine", title = "Structural myocardial alterations in diabetes and hypertension: the role of galectin-3", volume = "52", number = "10", pages = "1499-1505", doi = "10.1515/cclm-2014-0265" }
Seferović, J., Lalić, N. M., Floridi, F., Tesić, M., Seferović, P. M., Giga, V., Lalić, K., Jotić, A., Jovičić, S., Colak, E., Salerno, G., Cardelli, P.,& Di Somma, S.. (2014). Structural myocardial alterations in diabetes and hypertension: the role of galectin-3. in Clinical Chemistry and Laboratory Medicine Walter de Gruyter Gmbh, Berlin., 52(10), 1499-1505. https://doi.org/10.1515/cclm-2014-0265
Seferović J, Lalić NM, Floridi F, Tesić M, Seferović PM, Giga V, Lalić K, Jotić A, Jovičić S, Colak E, Salerno G, Cardelli P, Di Somma S. Structural myocardial alterations in diabetes and hypertension: the role of galectin-3. in Clinical Chemistry and Laboratory Medicine. 2014;52(10):1499-1505. doi:10.1515/cclm-2014-0265 .
Seferović, Jelena, Lalić, Nebojša M., Floridi, Federico, Tesić, Milorad, Seferović, Petar M., Giga, Vojislav, Lalić, Katarina, Jotić, Aleksandra, Jovičić, Snežana, Colak, Emina, Salerno, Gerardo, Cardelli, Patrizia, Di Somma, Salvatore, "Structural myocardial alterations in diabetes and hypertension: the role of galectin-3" in Clinical Chemistry and Laboratory Medicine, 52, no. 10 (2014):1499-1505, https://doi.org/10.1515/cclm-2014-0265 . .